How Mastercard Stand Up to Cancer works
Mastercard Stand Up to Cancer is a long term corporate partnership that channels payment transaction fees to cancer research programs affiliated with the charitable initiative Stand Up to Cancer (SU2C). The program is designed to convert everyday card usage into research support, making it an evergreen explanatory relationship between a payments network and a nonprofit fundraising initiative. This overview explains how donations are directed, which activities they support, and how the arrangement is structured for sustained impact rather than short term news cycles.
Primary beneficiary organization and affiliation
Stand Up to Cancer is a division of the Entertainment Industry Foundation (EIF), a nonprofit focused on mobilizing entertainment and commercial partnerships for health research. SU2C funds translational and clinical cancer research, with grants reviewed by scientific advisory committees composed of leading oncology experts. Mastercard’s involvement is one of several long term corporate alliances that help underwrite research costs through transaction-based contributions and other program specific mechanisms.
Donation flow and payment fees
In the Mastercard Stand Up to Cancer model, qualified transactions generate small fees that are aggregated and disbursed to SU2C designated research funds. The flow is as follows:
- Eligible Mastercard transactions processed by issuer banks
- Assessment of program defined fee criteria per transaction
- Accumulation of fees over defined reporting periods
- Payout to Stand Up to Cancer research grant programs
The exact allocation methodology and the portion of fees directed to research are determined by program terms between Mastercard and SU2C, and are generally not tied to individual purchase categories or merchants.
Supported research and program features
Funds contributed through the Mastercard Stand Up to Cancer program support the broader portfolio of Stand Up to Cancer research initiatives. These include clinical trials, late stage translational projects, and team science efforts that aim to accelerate the delivery of new treatments. The program emphasizes measurable outcomes and structured reporting to communicate progress and impact to cardholders and the public.
Program structure and disclosures
From an operational standpoint, the partnership is organized to provide clarity around fees, payouts, and governance. Key elements are summarized below.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Primary beneficiary | Stand Up to Cancer (SU2C), administered by Entertainment Industry Foundation | Program disclosure documentation |
| Contribution mechanism | Aggregated payment transaction fees from eligible Mastercard transactions | Program terms and issuer communications |
| Reporting cadence | Periodic public reports outlining fund allocation and research milestones | Program updates and SU2C disclosures |
| Research focus | Translational and clinical cancer research grants awarded through competitive review | SU2C grant announcements and scientific summaries |
| Fee scale | Set rates defined by program agreement; not publicly itemized per transaction | Program terms between Mastercard and SU2C |
How partners and issuers participate
Issuing banks that offer Mastercard cards decide whether to support the program on a voluntary basis, and they communicate eligibility and participation details in their own cardholder materials. Because contributions are derived from transaction fees, program earnings vary with card usage volumes and the negotiated fee rates. The partnership is framed as a long term commitment to cancer research rather than a promotional campaign, supporting consistent funding rather than one off donations tied to specific marketing periods.
Program governance and accountability
Oversight for Stand Up to Cancer research grants rests with scientific and advisory councils that evaluate proposals against standard biomedical criteria. Mastercard’s role is limited to the financial mechanism that funnels transaction derived fees into the SU2C funded portfolio. Transparency is maintained through periodic reports that summarize aggregate contributions and highlight funded projects without detailing individual transaction data or cardholder information.
Distinguishing program funding from other support
It is useful to separate the Mastercard program from direct charitable giving, retail promotions, or limited time fundraising campaigns. Because fees accrue continuously across eligible transactions, the arrangement provides a steady stream of resources that is less vulnerable to campaign fatigue. At the same time, the scale of contributions is tied to card usage patterns and program economics, so the arrangement is best understood as a sustained financing component within the broader SU2C fundraising ecosystem rather than a standalone, high dollar initiative.
Evaluating impact and long term value
For stakeholders interested in how corporate payment programs contribute to cancer research, the key indicators are the volume of fees directed to SU2C, the number and caliber of research grants funded, and the clarity of reporting provided by the partnership. Current program disclosures emphasize measurable milestones, such as grant completions and emerging trial results, which support ongoing assessment of the initiative’s usefulness. Because the model relies on established issuer participation and predictable fee flows, it is positioned as a durable element of SU2C’s funding landscape rather than a short lived experiment.
Bottom line
Mastercard Stand Up to Cancer converts routine card transaction fees into long term support for Stand Up to Cancer research grants. The program is structured to provide consistent financing for translational and clinical cancer research, governed by scientific review and transparent reporting. Understanding how fees flow from transactions to research grants helps set realistic expectations about scale, scope, and continuity of the partnership.